(BEAT) Heartbeam - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US42238H1086
BEAT: Electrocardiogram, Diagnostic Software, Cardiac Monitoring Systems
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company specializing in the development and commercialization of advanced ambulatory electrocardiogram (ECG) solutions. The companys technology enables the detection and monitoring of cardiac diseases both in clinical settings and remotely. HeartBeams innovative approach involves creating three-dimensional vector images of cardiac electrical activity, providing a more comprehensive view of heart function compared to traditional ECG methods.
The companys flagship product, HeartBeam AIMIGo, is a credit card-sized, cloud-based diagnostic system designed for the early detection of heart attacks. This portable solution aims to improve patient outcomes by enabling timely and accurate diagnosis outside of traditional healthcare facilities. HeartBeam Inc. was founded in 2015 and is headquartered in Santa Clara, California, a hub for medical technology innovation. For more information, visit their website at https://www.heartbeam.com.
HeartBeam operates in the Health Care Equipment sector, with a focus on developing cutting-edge solutions for cardiac care. The companys ticker symbol is BEAT, listed on the NASDAQ exchange as a common stock. Its market capitalization is approximately $68.13 million USD, with a price-to-book ratio of 13.70, indicating strong investor confidence in its growth potential.
Additional Sources for BEAT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BEAT Stock Overview
Market Cap in USD | 68m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2021-11-11 |
BEAT Stock Ratings
Growth 5y | -32.9% |
Fundamental | -13.1% |
Dividend | 0.0% |
Rel. Strength Industry | -11.6 |
Analysts | 4/5 |
Fair Price Momentum | 1.81 USD |
Fair Price DCF | - |
BEAT Dividends
No Dividends PaidBEAT Growth Ratios
Growth Correlation 3m | -69.9% |
Growth Correlation 12m | 2.1% |
Growth Correlation 5y | 1.8% |
CAGR 5y | -22.35% |
CAGR/Max DD 5y | -0.28 |
Sharpe Ratio 12m | -1.43 |
Alpha | -18.93 |
Beta | 0.73 |
Volatility | 75.88% |
Current Volume | 27.1k |
Average Volume 20d | 76.9k |
As of March 14, 2025, the stock is trading at USD 2.02 with a total of 27,072 shares traded.
Over the past week, the price has changed by -4.72%, over one month by -7.34%, over three months by -35.26% and over the past year by -11.79%.
Neither. Based on ValueRay Fundamental Analyses, Heartbeam is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -13.11 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BEAT as of March 2025 is 1.81. This means that BEAT is currently overvalued and has a potential downside of -10.4%.
Heartbeam has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy BEAT.
- Strong Buy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, BEAT Heartbeam will be worth about 2 in March 2026. The stock is currently trading at 2.02. This means that the stock has a potential downside of -0.5%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 5 | 147.5% |
Analysts Target Price | 5 | 147.5% |
ValueRay Target Price | 2 | -0.5% |